L Runkel

Summary

Affiliation: Biogen Inc
Country: USA

Publications

  1. ncbi request reprint Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta)
    L Runkel
    Biogen, Inc, Cambridge, Massachusetts 02142, USA
    Pharm Res 15:641-9. 1998
  2. ncbi request reprint The structure of human interferon-beta: implications for activity
    M Karpusas
    Biogen Inc, 14 Cambridge Center, Cambridge, Massachusetts 02142, USA
    Cell Mol Life Sci 54:1203-16. 1998
  3. ncbi request reprint Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis
    L Runkel
    Biogen, Inc, Cambridge, MA 02142, USA
    J Interferon Cytokine Res 21:931-41. 2001

Collaborators

Detail Information

Publications3

  1. ncbi request reprint Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta)
    L Runkel
    Biogen, Inc, Cambridge, Massachusetts 02142, USA
    Pharm Res 15:641-9. 1998
    ..The structural basis for activity differences between IFN-beta-1a and IFN-beta-1b, is determined...
  2. ncbi request reprint The structure of human interferon-beta: implications for activity
    M Karpusas
    Biogen Inc, 14 Cambridge Center, Cambridge, Massachusetts 02142, USA
    Cell Mol Life Sci 54:1203-16. 1998
    ..Finally, these structural implications are discussed in the context of the clinical use of HuIFN-beta...
  3. ncbi request reprint Mapping of IFN-beta epitopes important for receptor binding and biologic activation: comparison of results achieved using antibody-based methods and alanine substitution mutagenesis
    L Runkel
    Biogen, Inc, Cambridge, MA 02142, USA
    J Interferon Cytokine Res 21:931-41. 2001
    ..Thus, neutralizing mAb may employ mechanisms other than steric blockade to inhibit directly the binding of receptor by cytokine, limiting their usefulness as tools to define precise receptor-ligand interaction sites...